Kornimate/medical-research-clean huggingface dataset:
effects of roux-en-y gastric bypass on gastro-intestinal hormone secretion and brain responses food pictures

Conditions: Obesity

Summary: this is a cross-sectional study enrolling * 11 weight-stable, formerly obese female patients 1-5 years after roux-en-y gastric bypass (rygb) * 11 age- and weight-matched female subjects * 10 normal weight (body mass index 19-25 kg/m2) subjects the following measurements will be performed in each participants in basal conditions (after an overnight fast) and after ingestion of a standard meal * electroencephalographic recordings of visually evoked potential after presentation of food- or non-food pictures * plasma concentration of metabolites (glucose, fatty acids), glucoregulatory hormones (insulin, glucagon), gastro-intestinal hormones (gastric inhibitory polypeptide (gip), glucagon-like peptide-1 (glp1), ghrelin,cholecystokinin (cck), and bile acids aims of this observational study are * to evaluate the effects of rygb on brain perception of food related visual stimulation * to search for relationships between rygb effects on brain responses and gastro-intestinal hormone secretion


Eligibility criteria:
inclusion criteria: * good apparent health * gender: female * age 18-50 * non-smoker exclusion criteria: * diabetes or antidiabetic medication * consumption of more than 50g alcohol per week * vegetarian or any special diet

Keywords: roux-en-y-gastric bypass brain responses to food gastrointestinal hormones bile acids
transplantation of autologous oral mucosal epithelial stem cell sheet for treating limbal stem cell deficiency disease

Conditions: Limbal Stem Cell Deficiency

Summary: the aim of this trials investigates the therapeutic effects of application autologous oral mucosal epithelial cell sheets in the treatment of limbal stem cell deficiency disease.

a number of external factors can result in limbal stem cell deficiency(lscd), causing pain, pathological corneal epithelium regeneration, inflammation reaction and seriously visual loss. for patients with unilaterally damaged eye, transplantation of limbal tissue from the healthy eye can be used in the past years in the risk of inducing limbal stem cell damaged in the healthy eye. while graft of human leukocyte antigen matched allogenic limbal stem cells require immune suppressive medications, it can cause side effects in the body. over the past 10 years, the clinical trials of application of cultured autologous oral mucosal epithelial cell sheet to treat lscd have been emerged as a promising strategy in many countries. however, little study has been reported in china. this study investigates the therapeutic effects of application autologous oral mucosal epithelial cell sheets in the treatment of limbal stem cell deficiency disease in china.

Eligibility criteria:
inclusion criteria: * male or female aged\>=18 years old * normal intraocular pressure * normal eyelid * no cataract and retinal disease * no ulcers and tumor in the mouth exclusion criteria: * severe systemic infection * history of acute phase of ocular and oral inflammation * history of hyper sensibility or allergy to antibiotics or serum * women who are or may be pregnant * patients with infectious diseases * patients with other complications
acute exposure to high altitude on pulmonary artery pressure and right heart function (echo) under exercise

Conditions: Pulmonary Hypertension

Summary: randomized crossover trial in patients with pulmonary hypertension (pah, cteph) to assess the acute response to high altitude (2500m above sea level) on pulmonary artery pressure and right heart function (echo) under exercise.

low altitude baseline measurements will be performed in zurich (460m asl) including echocardiography, right heart catheterization, six-minute walk test (6mwt), pulmonary function test, clinical assessment and blood gas analysis. randomly assigned to the order of testing, the participants will be tested in low altitude (zurich, 470m) and at high altitude (2500m). several times within the exposure, the pulmonary artery pressure and the right heart function will be assessed by echo under exercise.

Eligibility criteria:
inclusion criteria * informed consent * ph diagnosed according to internation guidelines: mpap ≥ 25 mmhg along with a pawp ≤15 mmhg during right heart catheterization at the time of initial diagnosis * ph class 1 (pah) or 4 (cteph) * stable condition, on the same medication for \> 4 weeks * patient live permanently at an altitude \< 1000m asl. exclusion criteria: * resting pao2 ≤7.3 kpa corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed) * severe daytime hypercapnia (pco2 \> 6.5 kpa) * susceptibility to high altitude related diseases (ams, hape, etc.) based on previous experienced discomfort at altitudes. * exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation * residence \> 1000m above sea level * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability * women who are pregnant or breast feeding

Keywords: high altitude pulmonary artery pressure echocardiography right heart function exercise
premenstrual syndrome and physical activity self-worth

Conditions: Premenstrual Syndrome

Summary: premenstrual syndrome (pms) negatively affects the quality of life of millions of women. pms is a common cyclic disorder characterized by somatic, cognitive, emotional and behavioral symptoms that usually occurs in young and middle-aged women, lasts during the luteal phase of the menstrual cycle and ends with the onset of menstruation.studies have shown that women with high pms symptoms are more inactive. physical activity participation in women affects a wide spectrum of self-perceptions, including knowledge, social, and emotional self-perceptions. by determining which physical, emotional, social and academic/knowledge areas are affected by women, increasing their participation in physical activity can be achieved. the subject of the study is to determine the symptom severity of women with and without premenstrual syndrome and to examine how premenstrual syndrome affects physical activity self-worth.

premenstrual syndrome (pms) negatively affects the quality of life of millions of women. pms is a common cyclic disorder characterized by somatic, cognitive, emotional and behavioral symptoms that usually occurs in young and middle-aged women, lasts during the luteal phase of the menstrual cycle and ends with the onset of menstruation.studies have shown that women with high pms symptoms are more inactive. physical activity participation in women affects a wide spectrum of self-perceptions, including knowledge, social, and emotional self-perceptions. by determining which physical, emotional, social and academic/knowledge areas are affected by women, increasing their participation in physical activity can be achieved. the subject of the study is to determine the symptom severity of women with and without premenstrual syndrome and to examine how premenstrual syndrome affects physical activity self-worth. a total of 296 women age of 18-35 participate in the research. participants were divide into two groups with and without premenstrual syndrome.

Eligibility criteria:
inclusion criteria: * volunteer to participate in the study * being 18-35 years old * being women * to be menstruating exclusion criteria: * evaluation form missing * not menstruating for 12 months or more * having any psychological diagnosis * being pregnant

Keywords: premenstrual syndrome women self-worth physical activity
home based massage and relaxation for sickle cell pain

Conditions: Sickle Cell Disease

Summary: the purpose of this study is to compare the effects of in-home, family-administered massage and in-home relaxation training on measures of physical status and health care utilization in a sample of african american adolescents age 15 years and older and adults with chronic pain associated with sickle cell disease who have been randomly assigned to six sessions of either family-administered massage or progressive muscle relaxation training.


Eligibility criteria:
inclusion criteria: * medically diagnosed with sickle cell disease, including hemoglobin ss disease, hemoglobin sd disease, hemoglobin sc disease, or sickle-thalassemia * self-report of having experienced chronic pain related to sickle cell disease during the past 30 days. * availability of a family member or friend who agrees to be trained to administer massages if the participant is randomized to the massage arm of the study. exclusion criteria: * sickle cell trait instead of sickle cell disease diagnosis. * diagnosis of disease in addition to sickle cell disease which requires regular use of pain medication. (please note, regular use of pain medication for sickle cell pain is not an exclusion)

Keywords: sickle cell pain sickle cell disease chronic pain alternative medicine/therapy complementary medicine massage therapy relaxation technique home-based therapy
ketones & mitochondrial heteroplasmy

Conditions: MELAS Syndrome; Mitochondrial Diseases

Summary: the current study is a prospective evaluation of the ability of ketosis to shift mitochondrial dna (mtdna) heteroplasmy in subjects harboring a known mutation in their mtdna at position 3243 (a\>g). subjects will be given supplemental medium chain triglycerides (mcts) for a period of 6 months. mtdna heteroplasmy will be measured 3 months prior to treatment, at treatment initiation, and 6 months after initiation. the primary objective of the current study is to determine if there is a shift in heteroplasmy in patients harboring the 3243 a\>g mtdna mutation to a more favorable (higher wild-type) profile while in a state of ketosis.

the current study is a prospective evaluation of the ability of ketosis to shift mitochondrial dna (mtdna) heteroplasmy in subjects harboring a known pathogenic mutation in their mtdna at position 3243 (a\>g). subjects will be induced in to ketosis by administration of supplemental medium chain triglycerides (mcts) for a period of 6 months. mtdna heteroplasmy will be assessed 3 months prior to treatment, at treatment initiation, and 6 months after initiation. the primary objective of the current study is to determine if there is a shift in heteroplasmy in patients harboring the 3243 a\>g mtdna mutation to a more favorable (higher wild-type) genotypic profile while in a state of ketosis.

Eligibility criteria:
inclusion criteria: 1. subject is informed and given ample opportunity to consider his/her participation and has given his/her written consent. 2. subject is willing and able to comply with all trial requirements. 3. subject harbors the 3243 a\>g mtdna mutation at a level detectable in blood. 4. female subjects of child-bearing potential must not be pregnant. female subjects of child-bearing potential (not surgically sterile or 2 years post-menopausal) must also agree to use appropriate contraceptive methods (abstinence, oral, injectable, implantable, or barrier) for the duration of the trial. 5. subject must not have diabetes mellitus. exclusion criteria: 1. subject is currently participating or has participated within the last 2 months in any clinical trial involving treatment of mitochondrial disorders with mct supplementation or induction of ketosis. 2. subject has a medical condition that could reasonably be exacerbated by ketone supplementation (including diabetes mellitus). 3. subject is unable to give reasonable informed consent/assent. 4. subject is a pregnant or nursing female.

Keywords: melas ketones medium chain triglycerides mct oil mitochondrial disorder heteroplasmy 3243ag subject is informed and given ample opportunity to consider his/her participation and has given his/her written consent. subject is willing and able to comply with all trial requirements. subject harbors the 3243 a>g mtdna mutation at a level detectable in blood. female subjects of child-bearing potential must not be pregnant. subjects must not have diabetes mellitus.
use of r-hlh (luveris) in donors previously treated with r-hfsh (gonal f)

Conditions: Outcome During r-hFSH Stimulation; Outcome During r-hFSH and r-hLH Stimulation

Summary: the purpose of the study is to compare the safety and efficacy of r-hlh to r-hfsh in the late follicular phase of young women undergoing controlled ovarian stimulation for oocyte donation.

while the role of fsh is considered the fundamental driver of folliculogenesis, the role of lh in this process is more controversial. fsh is associated with stimulating growth and recruitment of follicles while lh is associated with the selection of dominant follicles destined for ovulation. we will use an open, prospective, cross-over study to compare the safety and efficacy of two different treatment protocols for controlled ovarian stimulation in egg donors. 20 participants will undergo two cycles of stimulation. the first one will be with r-hfsh though the cycle and the second with r-hfsh then r-hlh. the participants will have 1 month rest cycle between the treatment cycles. r-hfsh doses will be adjusted according to patient response. r-hlh dosing will begin when there are 2 follicles greater than or equal to 14mm in diameter. the does will be 300iu/day and continue until the day of r-hcg administration.

Eligibility criteria:
inclusion criteria: 1. age less than or equal to 32 years old 2. bmi\<35 3. eligible for controlled ovarian simulation 4. no pco-type ovaries (pco by uss image, \>2.1 lh;fsh ratio on cycle day 3, insulin resistance, increase of testosterone over free testosterone) 5. meet all requirements for becoming an egg donor 6. willingness and ability to participate and comply with study protocol for the duration of the study 7. baseline fsh\<11 exclusion criteria: 1. clinically significant systemic disease 2. any contraindication to gonadotropin therapy 3. lh:fsh ratio greater than 3 4. pregnancy in the past 3 months 5. any medical condition which, in the judgment of the investigator may interfere with the absorption, distribution, metabolism or excretion of the drug 6. simultaneous participation in another clinical trial 7. known active substance abuse, including tobacco and alcohol (\>10 cigarettes/day) 8. refusal or inability to comply with protocol 9. known poor ovarian response

Keywords: r-hfsh r-hlh
incidence of hyponatremia in peg-sd compared to peg-els

Conditions: Hyponatremia

Summary: objective: to compare the incidence of peri-colonoscopy hyponatremia associated with peg 3350 + sports drink (peg-sd) versus peg 3350-electrolyte solution + sodium sulfate + sodium ascorbate and ascorbic acid (peg-els). hypothesis: as compared to peg-sd, hyponatremia occurs significantly less often with peg-els.

looking at the incidence of hyponatremia with two commonly prescribed purgatives for colonoscopy-polyethylene glycol 3350 with a sports drink (peg-sd) compared to polyethylene glycol 3350 with electrolyte solution (peg-els)

Eligibility criteria:
inclusion criteria: * adults age 18 years or older scheduled for elective outpatient colonoscopy: 8am - noon. exclusion criteria: * unable or unwilling to consent * pregnant * breast feeding * significant psychiatric illness -\> 50% colon resection * bowel obstruction * history of hyponatremia (serum sodium \<135 mmol/l) * end stage renal disease on dialysis * history of chronic kidney disease (other than kidney stones) * decompensated cirrhosis, including: * history of bleeding due to portal hypertension (varices, gastropathy, etc) within 3 months * hepatic encephalopathy (not controlled with medications) within 3 months * clinical presence of ascites * active cardiac disease * recent myocardial infarction (\<4weeks) * unstable angina * congestive heart failure nyha functional class stage iii or iv * stage iii: marked limitation of activity. less than ordinary activity (e.g. walking short distances, 20-100 m) causes fatigue, palpitations, dyspnea. comfortable at rest. * stage iv: severe limitations. experiences symptoms even while at rest. mostly bedbound patients. exclusion criteria (post-enrollment), from baseline labs: * serum creatinine \> 1.5 mg/dl * serum potassium \ 5.5 mmol/l * serum sodium \ 150 mmol/l * serum calcium \ 11.0 mg/dl

Keywords: hyponatremia peg-sd peg-els
dynamic arterial elastance during general anesthesia induction

Conditions: Anesthesia

Summary: this study evaluates if dynamic arterial elastance measured before general anesthesia induction can predict the occurrence of hypotension due to general anesthesia induction.

as general anesthetics may be responsible for vasodilation and cardiac depression, arterial hypotension after induction of general anesthesia is a common event and may contribute to an adverse outcome. dynamic arterial elastance has been proposed as a functional parameter of arterial tone and studies showed that it was able to predict pressure response to fluid administration in fluid-responsive patients and the amount of mean arterial pressure riduction as a conseguence of noradrenaline dose reduction in critically ill patients.

Eligibility criteria:
inclusion criteria: * patients that will be undergone to general anesthesia for surgery * patients that need mini-invasive cardiac output monitoring during surgery exclusion criteria: * age \<18 yo * pregnancy * arrhythmia * severe valvular diseases * uncorrectable alterations of arterial signal
enhancing brain training with virtual reality

Conditions: Mild Traumatic Brain Injury

Summary: the purpose of this study is to evaluate the effectiveness of brain training in a virtual reality set up in neurotypical populations as well as in the traumatic brain injury population.

brain training is a large and a growing field, both scientifically and commercially. emerging evidence demonstrates that training can promote beneficial brain plasticity in both healthy individuals and clinical populations. much of the recent interest in brain training can be traced back to the seminal work done at the university of rochester, where daphne bavelier and colleagues showed that training with action video games (avg) can lead to a wide range of cognitive and perceptual improvements. in our recent work, we developed a novel training paradigm that isolates and concentrates the key aspects of avg-training while eliminating complex and often violent gameplay associated with avgs. the results revealed similarly broad effects of training as with conventional avgs. in this study, we aim to move this training paradigm to virtual reality (vr) and extend its application to cognitive aging and mild traumatic brain injury (tbi) populations.

Eligibility criteria:
inclusion criteria: a person is eligible for inclusion in the study if he/she: * is an adult over the age of 18. * has the capacity to give consent. * has normal or corrected to normal vision. * has adequate hearing. * is a non-action video game player. * is a non-vr game player. all subjects will be assigned to one of four groups: a control group training in vr, a control groups training on a 2d display, an older adult group without dementia training in vr, and a college athletes with mild tbi group training in vr. specific inclusion criteria for both control groups. the subject must: * be between the ages of 18 and 35. * have no neurologic or vascular disorders/injuries. specific inclusion criteria for the college athletes with tbi group. the subject must: * be between the ages of 18 and 35. * be diagnosed with mild tbi (i.e., concussion) within the last two weeks. specific inclusion criteria for the older adult group. the subject must: * be over the age of 65. * have no neurologic or vascular disorders/injuries. exclusion criteria: a person will be excluded from the study if he/she: • is under the age of 18.
efficacy and safety of subcutaneous administration of tev-48125 for the preventive treatment of chronic migraine

Conditions: Migraine

Summary: to evaluate the efficacy and safety of subcutaneous (sc) administration of tev-48125 \[monthly tev-48125 225 mg (loading dose only: 675 mg) and tev-48125 675 mg once over a period of 3 months\] compared with placebo for preventive treatment in chronic migraine patients


Eligibility criteria:
inclusion criteria: * patient has a history of migraine (according to the international classification of headache disorders, third edition \[beta version\] criteria) or clinical judgment suggests a migraine diagnosis * patient fulfills the criteria for chronic migraine in baseline information collected during the 28 day screening period * not using preventive migraine medications for migraine or other medical conditions or using no more than 1 preventive migraine medication for migraine or other medical conditions if the dose and regimen have been stable for at least 2 months prior to giving informed consent. * patient demonstrates compliance with the electronic headache diary during the screening period by entry of headache data on a minimum of 24 of 28 days and the entered data is judged appropriate by the investigator. exclusion criteria: * patients who have previously failed (lack of efficacy) 2 or more of the clusters of the medications for treatment of migraine after use for at least 3 months at accepted migraine therapeutic doses * patient suffers from unremitting headaches, defined as having headaches for more than 80% of the time that he/she is awake, and less than 4 days without headache per month. daily headache is acceptable if the patient has headaches 80% or less of the time they are awake on most days. * hematological, cardiac, renal, endocrine, pulmonary, gastrointestinal, genitourinary, neurologic, hepatic, or ocular disease considered clinically significant in the judgment of the investigator
gnrh agonist trigger and modified luteal phase support, adding a bolus of gnrha at the time of implantation - a rct

Conditions: Infertility

Summary: purpose:the aim of this project is to prospectively determine whether a single dose of gnrh-agonist administered at the time of implantation increases or not the reproductive outcome in patients undergoing in vitro fertilization ( ivf)/ intracytoplasmatic sperm injection(icsi) triggered by a gnrh-agonist followed by a small bolus of human chorionic gonadotropin (hcg 1500 iu) the day of oocyte retrieval. acronyms: gnrh: gonadotropin-releasing hormone fsh: follicle stimulating hormone lh: luteinizing hormone hcg:human chorionic gonadotropin ivf:in vitro fertilization icsi:intracytoplasmatic sperm injection ohss:ovarian hyperstimulation syndrome omega: oocyte maturation employing gnrh-agonist opu: ovum pick up nacl: sodium chloride

it has been reported in previous publications that the ovarian hyperstimulation syndrome (ohss) was eliminated when gnrh agonist was used to trigger ovulation and the delivery rate has improved after modified luteal support especially when a small bolus of hcg is used on the day of oocyte retrieval. (omega/hcg 1500 iu). however, a risk difference of 7% in delivery rates is still in favor of hcg trigger. thus, further modifications in the luteal phase supplementation are required in order to optimise the reproductive outcome after gnrh-agonist triggering. recently, many papers showed, that independently of the gnrh analogue used to prevent the premature lh surge, the addition of gnrh-agonist during the luteal phase seems to be beneficial in terms of pregnancy. nevertheless, their use in practice is not yet admitted because of controversial results in terms of efficacy and safety particularly on the conceptus.

Eligibility criteria:
inclusion criteria: * female age \< 40 years * baseline fsh and lh \< 12 iu/l. * body mass index \> 18 and \< 35 kg/m2 * no uterine (fibroids, mullerian malformations), ovarian ( endometrioma) or adnexa (hydrosalpinx) abnormalities * patients with at least one embryo at transfer time exclusion criteria: * very high risk of ohss (\> 30 follicles \> 12 mm the day of ovulation triggering). * reduced ovarian reserve * fertilization failure * severe endocrinopathy * azoospermia

Keywords: gnrh agonist gnrh antagonist luteal phase